Autologous ovarian cancer cells

Autologous ovarian cancer cells represent a personalized therapeutic target entity used in the development of patient-specific cancer vaccines and adoptive cell therapies [1, 2]. Unlike conventional targeted therapies that focus on a single protein, this approach utilizes the whole cancer cell to present the complete repertoire of tumor-associated antigens and neoantigens unique to an individual's disease [11, 13]. These cells are typically harvested during surgical debulking and then processed—through genetic modification, irradiation, or inactivation—to enhance their immunogenicity or suppress their inherent immune-evasive properties [2, 3]. For instance, the vaccine Gemogenovatucel-T (Vigil) involves modifying these cells to express GM-CSF and knock down TGF-beta, thereby actively stimulating the immune system to recognize and destroy residual tumor cells [3, 4]. Biological functions of these target cells include rapid proliferation, spheroid formation in the peritoneal cavity, and the secretion of immunosuppressive cytokines to evade detection [7, 14, 15]. The primary goal of targeting these cells is to overcome the high degree of tumor heterogeneity and the immunosuppressive microenvironment characteristic of advanced ovarian cancer [16, 17]. This personalized strategy aims to provide a durable anti-tumor response and prevent recurrence in patients who have become resistant to standard platinum-based chemotherapy [12, 18].

Other names

Patient-specific ovarian cancer cellsAutologous tumor cells (Ovarian)Primary ovarian cancer cellsAutologous epithelial ovarian cancer cells

Induction of a polyvalent, patient-specific immune response by presenting the full repertoire of tumor-associated neoantigens to the host's immune system, typically combined with ex vivo processing to enhance immunogenicity and reduce tumor-mediated immunosuppression.